SAFETY DATA SHEETS

This SDS packet was issued with item:

078946100

The safety data sheets (SDS) in this packet apply to the individual products listed below. Please refer to invoice for specific item number(s).

078946097 078946098 078946099 078946101 078946102

SECTION 1: IDENTIFICATION	
1.1 Product identifier	
Product name	Enroquin (enrofloxacin) Flavored Tablets 22.7 mg, 68 mg and 136 mg
Synonyms	Not available
Proper shipping name	Not available
Other means of identification	None
1.2 Relevant identified uses of the substances or mixture and uses advised against	
Recommended uses	Antibacterial for professional use only. Federal law restricts this drug to be used by or on the order of a licensed veterinarian.
Uses advised against	Not for human use
1.3 Details of the supplier of the substance or mixture	
Registered company name	Dechra Veterinary Products
Address	7015 College Blvd Suite 525 Overland Park KS 66211 USA
Telephone	866-933-2472
Fax	Not available
Email	Not available
1.4 Emergency telephone numbers	
Dechra (US)	866-933-2472

SECTION 2: HAZARDS IDENTIFICATION
2.1 Classification of the substance or mixture
Classification (GHS-US)
This product is a drug, as defined by the US Food, Drug, and Cosmetic Act (21 U.S.C. 301 et seq.). It is in solid, final form for direct administration to the patient. Therefore, it is exempt from the US 2012 Hazard Communication Standard, as defined in the 29 CFR 1910.1200(b)(6)(vii).
2.2 Label elements
No labeling applicable
2.3 Other Hazards
No additional information available
2.4 Unknown Acute Toxicity (GHS-US)
No data available

SECTION 3: COMPOSITION/INFORMATION ON THE INGREDIENTS
3.1 Substances
See section below for composition of Mixtures.

3.2 Mixtures		
CAS No	**Approximate Quantity**	**Name**
93106-60-6	2.27/68/136 mg	enrofloxacin
Not applicable	q.s.	Non-hazardous Ingredients

SECTION 4: FIRST AID MEASURES

4.1 Description of first aid measures

General advice:
If you feel unwell, seek medical advice.

Eye contact:
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician if irritation persist.

Skin contact:
Wash off with soap and plenty of water. Consult a physician if irritation persist.

Inhalation:
The risk of inhalation exposure is negligible when product is in its final packaged form. If exposed and become symptomatic, move to fresh air and get medical attention if symptoms persist.

Ingestion:
Consult a physician.

4.2 Most important symptoms and effects, both acute and delayed

Inhalation:
Due to the product's final form, inhalation is an unlikely route of exposure.

Skin contact:
None expected under normal conditions of use,

Eye contact:
None expected under normal conditions of use.

Ingestion:
Ingestion of the product is likely to be harmful or have adverse effects.

Chronic symptoms:
None expected under normal conditions of use.

4.3 Indication of any immediate medical attention and special treatment needed:

Treat symptomatically.

SECTION 5: FIRE FIGHTING MEASURES

5.1 Extinguishing media

Suitable extinguishing media: Use extinguishing media appropriate for surrounding fire.
Unsuitable extinguishing media: None known.

5.2 Special hazards arising from the substance or mixture

Fire hazard: Not considered flammable.
Explosion hazard: Product itself is not explosive.
Reactivity: Hazardous reactions will not occur under normal conditions.

Special fire fighting procedure: Fire may cause release of carbon monoxide, carbon dioxide. In the event of fire, wear self-contained breathing apparatus. Prevent fire. Prevent water from contaminating surface water or the ground water system.

5.3 Advice for fire-fighters:

Precautionary measures fire: Exercise caution when fighting any chemical fire.
Firefighting instructions: Use water spray or fog for cooling exposed containers.
Protection during firefighting: Do not enter fire area without proper protective equipment, including respiratory protection.

SECTION 6: ACCIDENTAL RELEASE MEASURES

6.1 Personal precautions, protective equipment and emergency procedures

General measures: Avoid unnecessary contact with skin, eyes and clothing.

6.1.1. For non-emergency personnel

Protective equipment: Use appropriate personal protection equipment (PPE).
Emergency procedures: Evacuate unnecessary personnel.

6.1.2. For emergency responders

Protective equipment: Equip cleanup crew with proper protection.
Emergency procedures: Upon arrival at the scene, a first responder is expected to recognize the presence of dangerous goods, protect oneself and the public, secure the area, and call for the assistance of trained personnel as soon as conditions permit**.**

6.2 Environmental precautions

Avoid release to environment.

6.3 Methods and material for containment and cleaning up

For containment	Contain and collect as any solid.
Methods for cleaning up	Dispose of waste in accordance with local, state and federal regulations.

6.4 References to other sections

See Heading 8. Exposure controls and personal protection. For further information refer to section 13.

SECTION 7: HANDLING AND STORAGE

7.1 Precautions for safe handling

Hygiene measures	Avoid contact with skin, eyes and clothing. Take measures to prevent the buildup of electrostatic charge. Keep away from open flames, hot surfaces and sources of ignition. Use appropriate personal protective equipment when handling and observe good personal hygiene measures after handling.

7.2 Conditions for safe storage, including any incompatibilities

Technical measures	Comply with applicable regulations.
Storage conditions	Store at 20° to 25°C (68° to 77°F), excursions permitted between 15° and 30°C (between 59° and 86°F). [See

	USP controlled room temperature]. Store tablets in a tight container only.
Incompatible Products	Strong acids. Strong bases. Strong oxidizers.

7.3 Specific end use(s)

Antibacterial. For professional use only. Federal (U.S.A.) law restricts this drug to be used by or on the order of a licensed veterinarian.

SECTION 8: EXPOSURE CONTROLS / PERSONAL PROTECTION

8.1 Control parameters

For substances listed in section 3 that are not listed here, there are no established exposure limits from the manufacturer, supplier, importer, or the appropriate advisory agency including: ACGIH (TLV), NIOSH (REL), or OSHA (PEL).

8.2 Exposure controls

Appropriate engineering controls	Avoid creating or spreading dust. Ensure adequate ventilation, especially in confined areas. Emergency eye wash fountains and safety showers should be available in the immediate vicinity of any potential exposure. Ensure all national/local regulations are observed.
Personal protective equipment	Not generally required. The use of personal protective equipment may be necessary as conditions warrant.
Hand protection	Wear protective gloves
Eye protection	If splashes are likely to occur, wear safety glasses with side-shields.
Skin and body protection	Wear suitable protective clothing if skin contact with drug product is possible.
Respiratory protection	No protection equipment is needed under normal use conditions. If exposure limits are exceeded or irritation is experienced, ventilation and excavation may be required.

SECTION 9: PHYSICAL AND CHEMICAL PROPERTIES

9.1 Information on basic physical and chemical properties

Appearance: Brown colored tablet.	**Vapor density:** NA
Physical state: Solid	**Auto ignition temperature (degrees C):** NA
Odor: NA	**Decomposition temperature (degrees C):** NA
Odor threshold: NA	**Viscosity (degrees C):** NA
pH (as supplied): NA	**Explosive properties:** NA
Melting point / freezing point (degrees C): NA	**Oxidizing properties:** NA
Initial boiling point and boiling range: NA	**Partition coefficient:** NA
Flash point: NA	**Molecular weight:** NA
Evaporation rate: NA	**Taste:** NA
Flammability: NA	**Surface tension:** NA
Upper/lower flammability or explosive limits: NA	**Volatile component:** NA
	Gas group: NA
Vapor pressure: NA	**pH as a solution:** NA

Relative density (at degrees C): NA **Solubility in water and solvents (mg/l):** NA	**VOC g/L:** NA **Specific gravity @ 20 degrees C (water = 1):** NA
9.2 Other information No additional information available	

10: REACTIVITY AND STABILITY	
10.1 Reactivity	Hazardous reactions will not occur under normal conditions.
10.2 Chemical stability	Stable under recommended handling and storage conditions.
10.3 Possibility of hazardous reactions	Stable under recommended handling and storage conditions.
10.4 Conditions to avoid	Direct sunlight. Extremes of temperatures.
10.5 Hazardous decomposition products	Decomposition will not occur under normal conditions

SECTION 11: TOXICOLOGICAL INFORMATION	
Acute toxicity	Oral LD_{50} (rat) >5000 mg/kg (enrofloxacin) Oral LD_{50} (mouse) 4336-5000 mg/kg (enrofloxacin) Inhalation LC_{50} (rat) >3547 mg/m^3 (enrofloxacin)
Local effects	Eye: slightly irritant to the eye. Skin: non-irritant to the skin. Non-sensitizing to the skin. Administration to animals over a period of several weeks at elevated dosages has produced changes in articular cartilage.
Reproductive effects	Chronic exposure (3 months to 2 years) of laboratory species to Enrofloxacin has produced testicular degeneration and associated adverse effects on spermatogenesis. None of the other ingredients of the formulation have been shown to produce reproductive or Teratogenic effects.
Mutagenicity	None of the ingredients of the formulation have been shown to produce mutagenic effects. Carcinogenic Effects: Enrofloxacin has been shown in animal tests to have no carcinogenic potential. Other ingredients are not classified as carcinogens.

SECTION 12: ECOLOGICAL INFORMATION
12.1 Toxicity: Toxic to aquatic life
12.2 Persistence and degradability: No additional information available
12.3 Bioaccumulative potential: No additional information available
12.4 Mobility in soil: No additional information available
12.5 Other adverse effects: No additional information available

SECTION 13: DISPOSAL CONSIDERATIONS

13.1 Waste treatment methods

Waste Disposal Recommendations: Dispose of waste material in accordance with all local, regional, national, and international regulations.

SECTION 14: TRANSPORT INFORMATION

Transport according to all local, state and federal regulation

SECTION 15: REGULATORY INFORMATION

Enroquin is approved for the bacterial infections in cats and Dogs. Enroquin is indicated for management of diseases associated with bacteria susceptible to Enrofloxacin.

SECTION 16: OTHER INFORMATION

The information provided in this Safety Data Sheet has been compiled by Dechra Veterinary Products LLC and is correct to the best of its knowledge, information and belief as of the date of its publication. However, Dechra Veterinary Products LLC makes no warranties, express or implied, in relation to the information set out in this Safety Data Sheet, including, without limitation, as to its accuracy or completeness. The information provided is not a quality specification, and is prepared by way of guidance as to the safe handling, use, processing, storage, transportation, disposal and release of the relevant products referred to. The user is responsible for determining whether or not the product is fit for any particular purpose and/or suitable for the user's proposed method of use and application.